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henotypic Plasticity of
arcomeric Protein Mutations*
li J. Marian, MD, FACC
ouston, Texas
he practice of medicine today is founded primarily on the
henotypic characteristics of diseases. The recognition of
ommon forms of cardiomyopathies as hypertrophic, di-
ated, restrictive, and arrhythmogenic right ventricular car-
iomyopathies typifies the phenotype-based approach to
iseases. The approach clearly has had numerous positive
mpacts on the diagnosis, prognostication, prevention, and
reatment of various diseases. The advent of the beta-
lockers and inhibitors of the renin-angiotensin-aldosterone
athway in the treatment of systolic heart failure are
estaments to the clinical utility of the phenotype-based
pproach. Despite the enormous impacts, however, the
henotype-based approach has considerable shortcomings.
or example, the approach has failed to offer a cure for many
iseases including systolic heart failure, in which pharma-
ologic interventions reduce mortality by approximately
0% to 30% and prolong survival by a few months (1–3).
See page 2419
ccordingly, the annual incidence of heart failure, the
ommon “end” phenotype of many cardiovascular diseases,
as increased to 550,000 cases (4). It affected approximately
.2 million individuals in the U.S. alone and accounted for
pproximately 1,100,000 hospitalizations and 57,000 deaths
n 2004 (4). The inherent problem of the phenotype-based
pproach to the practice of medicine is that it does not
rovide sufficient information on the cause and/or the
athogenesis of the disease. To cure a disease, it is necessary,
t least in most cases, to understand the cause and the
athways involved in the pathogenesis of the phenotype.
The dawning of modern molecular genetics has raised the
ossibility of a switch from a phenotype-based to a
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
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urroughs Wellcome Fund, and The TexGen Fund from Greater Houston Com-
unity Foundation.enotype-based approach to medicine. Elucidation of the
olecular genetic basis of various cardiovascular diseases,
lthough yet incomplete, has led to the categorization of the
henotypes according to their genetic etiology. For example,
ypertrophic cardiomyopathy (HCM) is considered a dis-
ase of sarcomeric proteins, dilated cardiomyopathy (DCM)
disease of cytoskeletal proteins, and long QT syndrome a
isease of ion channels. The clear advantages of the
enotype-based as opposed to a phenotype-based approach
re in early diagnosis of those at risk, before and indepen-
ent of the clinical phenotype as well as in the accurate
iagnosis of the true phenotype from phenocopy conditions.
he clinical significance of the first advantage is evident by
he possibility of interventions to prevent the evolving
henotype. The utility of an accurate diagnosis and distinc-
ion from a phenocopy state is well illustrated in certain
ircumstances, such as Fabry disease, which could be clini-
ally indistinguishable from HCM caused by mutations in
arcomeric proteins (5,6). Enzyme replacement therapy
ith alpha-galactosidase, the enzyme responsible for Fabry
isease, has been shown to impart considerable clinical
enefit in management of patients with Fabry disease, while
he conventional treatment offered for true HCM would
ender no significant benefit in such patients (7).
The genotype-based approach, however, is compounded
y the genetic heterogeneity of each specific phenotype. It is
ow evident that a large number of mutations in different
enes, albeit largely within the same class, could cause the
ame phenotype. Moreover, mutations in one gene could
ause multiple phenotypes, as best illustrated in the case of
amin A/C, whereby mutations can cause 13 different
iseases, including DCM, conduction defects, Emery
reifuss muscular dystrophy, familial partial lipodystrophy,
remature aging, axonal neuropathy, and insulin resistance
8). Likewise, it is also intriguing that mutations in the same
ene and even the same mutation in different background
ause disparate phenotypes (8). In the case of cardiomyop-
thies, such phenotypic plasticity was best illustrated by Dr.
eidman’s group, who reported that mutations in the
YH7 and TNNT2, encoding beta-myosin heavy chain and
ardiac troponin T, respectively, could cause either HCM or
CM, the opposite ends of the spectrum of phenotypic
esponses of the heart to injury, stress, or mutations (9). The
eport by Kubo et al. (10) in this issue of the Journal expands
n the phenotypic plasticity of sarcomeric protein muta-
ions. In a study of 1,226 patients from 688 families with the
linical diagnosis of HCM, Kubo et al. (10) detected a
estrictive phenotype, resembling restrictive cardiomyopathy
RCM) in 19 individuals from 16 families. The phenotype
as characterized by mild or no left ventricular hypertrophy,
reserved left ventricular systolic function, restrictive mitral
nflow pattern on Doppler echocardiography, enlarged atria,
nd a high rate of mortality (10). Interestingly, 8 probands
ad mutation either in the MYH7 or TNNI3, encoding
ardiac troponin I. The findings that HCM could present,
y
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Editorial Comment June 26, 2007:2427–9et uncommonly, with a restrictive phenotype resembling
CM and the high mortality rate associated with a restric-
ive physiology are noteworthy and have clinical implica-
ions. The phenotypic plasticity of sarcomeric protein mu-
ations reported by Kubo et al. (10) is also in accord with
revious reports from Dr. McKenna’s group, Dr. Seidman’s
roup, and others (9,11,12). Collectively, the data show
utations in sarcomeric proteins can present phenotypically
s HCM, DCM, or RCM.
The molecular basis of phenotypic plasticity of sarcomeric
rotein mutations is unknown. It is likely to be multifacto-
ial and partly determined by the impact of the mutant
rotein on sarcomere structure and function, the unit of
ontraction and relaxation in the striated muscle. Complex
echanisms govern assembly and function of the sarco-
eres. The complexity affords the mutant proteins the
pportunity to impart a diverse array of effects spanning
rom the assembly of the filaments, protein-protein inter-
ctions to Ca2 sensitivity of the acto-myosin interaction.
he motor molecule of the acto-myosin interaction is
yosin heavy chain, which exists in a hexameric complex
omprised of 2 myosin heavy chain proteins, and 2 regula-
ory and 2 essential light chains. The partner for MyHC in
ontraction and relaxation is cardiac alpha-actin, which is a
omponent of the thin filaments. Association and dissocia-
ion of MyHC and actin is regulated by a series of proteins
ncluding the troponin-alpha-tropomyosin complex. Other
onstituents, such as obscurin, myosin binding protein C,
itin, and Z-disc proteins also play important roles in the
egulation of sarcomere structure and function. Electrical
epolarization of the cell membrane opens the L-type
alcium channels and allows Ca2 influx, which incites the
ynamic interactions between the sarcomeric proteins. The
nflux opens the ryanodine receptors and releases Ca2 from
arcoplasmic reticulum. The released Ca2 binds to cardiac
roponin C and induces conformational changes in the
roponin-alpha-tropomyosin complex. The change dis-
laces cTnI, the inhibitory protein of the complex, from
ctin and allows association of actin and MyHC. In the
elaxed state, the globular head of MyHC is bound to
denosine triphosphate (ATP). Upon binding to actin,
yHC hydrolyzes ATP to adenosine diphosphate (ADP)
nd inorganic phosphate. The ADP-bound MyHC globu-
ar head generates the working stroke by displacing the actin
lament by several nanometers and generating several
icoNewton force (13). Uptake of Ca2 by the sarcoplasmic
eticulum reverses the process, and replacement of ADP by
TP returns the sarcomeres to the relaxed state. Thus, the
henotypic plasticity of mutant sarcomeric proteins could be
artly explained by the effect of mutant proteins on different
tructural and regulatory components of the force genera-
ion and relaxation complex. In support of this hypothesis,
utations in cTnT, known to cause HCM in humans,
nhance Ca2 sensitivity of myofilament force-generation
nd ATPase activity (14,15). In contrast, those leading to
CM impart opposite effects (16–18). Likewise, our pre- aiminary data show cTnI, the inhibitory protein of the
cto-myosin interaction, exhibits a lower affinity for cardiac
lpha-actin in the presence of the cTnT-Q92, known to
ause HCM (19). The opposite is the case in the presence
f cTnT-W141, responsible for DCM in humans (19).
hus, the existing data could provide some explanations for
he contrasting phenotypes of HCM and DCM arising
rom mutations in the same gene, which are primarily based
n the differential effects of the mutant proteins on force
eneration and ATPase activity. However, there is a paucity
f information to explain the molecular mechanisms re-
ponsible for RCM phenotype arising from mutant sarco-
eric proteins. Speculations include impaired ATP-
ediated dissociation of myosin from actin, leading to
mpaired myocardial relaxation and a restrictive physiology.
lternatively, mutant protein could affect function of titin
soforms, implicated in myocyte stiffness (20), and phos-
horylation of sarcomeric proteins.
The clinical phenotype of a genetic disorder arises from
ore information than is contained in the causal deoxyri-
onucleic acid sequence or the mutation. The levels of
omplexity that govern evolution of the phenotype in
ardiomyopathies can not be solely restricted to differential
nteractions between the constituents of the sarcomeric
roteins. Such differential interactions alone are insufficient
o explain phenotypic plasticity resulting from the same
utation in a given gene (8,11). The point is exemplified by
previous work also from Dr. McKenna’s group showing
utations in TNNI3 causing either HCM or RCM in
embers of the same family (11). One could speculate on
he potential determinants of the ensuing phenotypes in
uch situations to include the effects of the modifier genes,
pigenetic factors, and post-transcriptional and translational
odifications of expressed proteins.
Genes contain information that is essential for the devel-
pment of the phenotype but not necessarily complete. Any
erturbation in the gene structure is expected to convey a
henotype, sometimes quite subtle, as in the case of complex
henotypes and occasionally drastic, as in the case of
ingle-gene disorders with Mendelian pattern of inheri-
ance. The mutation is the instigator but not the sole
eterminant of the clinical phenotype. The final phenotype
s determined not only by the causal mutation but also by
he modifier genes, each exerting a modest effect, epigenetic
actors, which link the gene to the phenotype, and the
nvironmental factors. Thus, while advances in molecular
enetics of cardiovascular diseases are gradually changing
ur classical understanding of the disease and the
henotype-based approach to the practice of medicine, they
re unlikely to be sufficient to trigger a full switch from a
henotype-based to genotyped-based medicine. The re-
earch emphasis must be not only in identification of the
ausal genes and mutation but also on delineating the
olecular mechanisms involved in the pathogenesis of
he phenotype. Only then can a comprehensive molecular
pproach, integrating the genetic, epigenetic, transcrip-
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June 26, 2007:2427–9 Editorial Commentomic, and proteomic profiles, be developed to propel
edicine toward the molecular-based diagnosis, prevention,
nd treatment, targeted to specific genes or pathways
nvolved in the pathogenesis of the phenotype.
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